| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1026849723 |
| P356 | DOI | 10.1007/S11906-015-0568-7 |
| P698 | PubMed publication ID | 26068660 |
| P50 | author | Sheldon W. Tobe | Q58091532 |
| P2093 | author name string | Donald E Kohan | |
| Ranjit Singarayer | |||
| P2860 | cites work | Avosentan reduces albumin excretion in diabetics with macroalbuminuria | Q24642372 |
| Canadian Society of Nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management | Q27008043 | ||
| Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy | Q28580979 | ||
| A novel potent vasoconstrictor peptide produced by vascular endothelial cells | Q29620540 | ||
| Avosentan for overt diabetic nephropathy | Q33702404 | ||
| Progression, remission, regression of chronic renal diseases | Q34264270 | ||
| Role of endothelin-1 in hypertension and vascular disease | Q34285581 | ||
| Chronic kidney disease: global dimension and perspectives | Q34347984 | ||
| Endothelin and endothelin antagonists in chronic kidney disease | Q34437692 | ||
| Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? | Q34660839 | ||
| Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy | Q34726905 | ||
| New therapeutics that antagonize endothelin: promises and frustrations | Q35013988 | ||
| Regulation of blood pressure and salt homeostasis by endothelin | Q35609851 | ||
| Hypertension in renal parenchymal disease: why is it so resistant to treatment? | Q36417735 | ||
| Clinical trials of endothelin antagonists in heart failure: a question of dose? | Q36495006 | ||
| Endothelin-1 and the kidney--beyond BP. | Q36619734 | ||
| Endothelin role in kidney acidification | Q36637549 | ||
| High glucose alters actin assembly in glomerular mesangial and epithelial cells | Q36682186 | ||
| Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism | Q36965292 | ||
| Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury | Q37211372 | ||
| Endothelin antagonists for diabetic and non-diabetic chronic kidney disease | Q37219055 | ||
| Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans. | Q37722848 | ||
| Endothelin and podocyte injury in chronic kidney disease | Q37926834 | ||
| Endothelin antagonism for patients with chronic kidney disease: still a hope for the future | Q38185016 | ||
| Endothelin receptors, renal effects and blood pressure. | Q38301944 | ||
| The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial. | Q40013771 | ||
| Angiotensin II stimulates endothelin-1 secretion in cultured rat mesangial cells | Q41086982 | ||
| Endothelins in the normal and diseased kidney | Q41323358 | ||
| Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling | Q41837398 | ||
| Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy | Q42283633 | ||
| Constitutive expression of endothelin gene in cultured human mesangial cells and its modulation by transforming growth factor-beta, thrombin, and a thromboxane A2 analogue. | Q42466255 | ||
| Endothelin production in cultured mesangial cells of spontaneously hypertensive rats | Q42486301 | ||
| Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial | Q42870194 | ||
| ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin | Q43054826 | ||
| A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial | Q43277549 | ||
| Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? | Q44123593 | ||
| Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial | Q44315403 | ||
| Avosentan is protective in hypertensive nephropathy at doses not causing fluid retention. | Q44328081 | ||
| Regulation of endothelin-1 production in cultured rat mesangial cells | Q44484903 | ||
| Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. | Q45977797 | ||
| Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus | Q46696790 | ||
| An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension | Q47644192 | ||
| Endothelin-induced endocytosis of cell surface ETA receptors. Endothelin remains intact and bound to the ETA receptor | Q49165131 | ||
| Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. | Q50789643 | ||
| Endothelin-receptor antagonists for diabetic nephropathy: A meta-analysis. | Q51000648 | ||
| Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). | Q53387958 | ||
| Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease | Q56987897 | ||
| Influence of Cardiovascular Damage and Residual Renal Function on Plasma Endothelin in Chronic Renal Failure | Q58951354 | ||
| Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD | Q59600909 | ||
| Comparative sensitivities of isolated rat renal arterioles to endothelin | Q67586610 | ||
| Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells | Q68340174 | ||
| Renal microvascular effects of endothelin | Q68534119 | ||
| Direct visualization of effects of endothelin on the renal microvasculature | Q68928651 | ||
| Localization of endothelin ETA and ETB receptor-mediated constriction in the renal microcirculation of rats | Q71851592 | ||
| Cardiac natriuretic peptides inhibit cyclosporine-induced production of endothelin in cultured rat mesangial cells | Q72618785 | ||
| Endothelin receptor subtype B mediates autoinduction of endothelin-1 in rat mesangial cells | Q72645728 | ||
| Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension | Q73086588 | ||
| ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension | Q74132786 | ||
| Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 tria | Q82766552 | ||
| Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease | Q83489879 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 57 | |
| P577 | publication date | 2015-07-01 | |
| P1433 | published in | Current Hypertension Reports | Q15746362 |
| P1476 | title | Endothelin Receptor Antagonists: New Hope for Renal Protection? | |
| P478 | volume | 17 |
Search more.